A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma

NCT ID: NCT01223209

Last Updated: 2012-01-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2012-01-31

Brief Summary

This study involves testing of the medicine LTX-315 combined with a cancer vaccine (GV1001). This will be tested in patients that have had surgery with curative intent for malignant tumour.

GV1001 is a peptide vaccine in development to treat cancer. An adjuvant, is required to start the immune response in the body to have effect of GV-1001.

LTX-315, also a peptide, in development for cancer treatment. In this study, the investigators wish to find out whether LTX-315 can make GV1001 more effective at stimulating the immune system.

Detailed Description

This clinical study has two main aims which are:

• To measure the immunological effects of LTX-315 in combination with GV1001
• Find out about the side effects of the combination of the two drugs This is an open label, single centre study assessing immunological effects and safety of LTX-315 given as an adjunct to GV1001. The LTX-315 dose will escalate while the GV1001 dose will be fixed.

LTX-315 and GV1001 will be given as intradermal injections on days 1, 8, 15, 22 and 36.

Investigational treatment: LTX-315 (0.10 mL) with escalating concentrations will be injected intradermally, followed, 1-2 hours later, by intradermal injection of 0.56 mg GV1001 (0.20 mL, 2.8 mg/mL) in the same site, in one arm.

DTH-test control: 0.10 mg GV1001 (0.10 mL) will be injected intradermally in the contralateral arm without LTX-315, as a DTH skin reactivity test control.

Conditions

Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Study Groups

LTX-315

The dose range of 0,25-2.0 mg/ML LTX-315 will be used. In combination with a fixed dose of GV-1001.

Group Type: EXPERIMENTAL

LTX-315

Intervention Type: DRUG

0.25-2.0 mg/ML, maximum 5 injections during 36 days.

Interventions

LTX-315

0.25-2.0 mg/ML, maximum 5 injections during 36 days.

Intervention Type: DRUG

Other Intervention Names

GV-1001

Eligibility Criteria

Inclusion Criteria

• Curative surgery for carcinoma performed at least three months prior to treatment start
• Age ≥18 years
• ECOG Performance status (PS): 0
• Life expectancy: at least 3 months
• Laboratory requirements:

• White Blood Count (WBC) ≥ 3 x 109/L
• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
• Platelet count ≥ 100 x 109/L
• Haemoglobin ≥ 10.0 g/dL
• Total bilirubin level ≤ 1.5 ULN
• AST and ALT ≤ 2.5 x ULN
• Creatinine ≥ 1.5 ULN
• Albumin > 30 g/L
• No expectation of anti-cancer therapy or immunotherapy during the trial period, hormone therapy given as adjunctive or contraceptive therapy is permitted
• Must be willing to practice acceptable barrier methods of birth control to prevent pregnancy
• The patient is willing and able to comply with the protocol and agrees to return to the hospital for follow-up visits and examination
• The patient has been fully informed about the study and has signed the informed consent form

Exclusion Criteria

• Has received an investigational drug within 4 weeks prior to study drug administration, or is scheduled to receive one during the treatment or the post-treatment period
• Has received immunotherapy or been vaccinated within 12 weeks prior to study drug administration or has not recovered from adverse events due to such agents
• Has received external radiotherapy or cytotoxic chemotherapy within the last 4 weeks prior to study drug administration, or has not recovered from adverse events (< Grade 1) due to agents administered more than 4 weeks earlier
• Has received imiquimod within 12 weeks prior to study drug administration or has not recovered from associated adverse events
• Is currently on any agent with a known effect on the immune system
• Has any other serious illness or medical condition such as but not limited to:

• Any uncontrolled infection or infection requiring antibiotics
• Uncontrolled cardiac failure Classification III or IV (New York Heart Association)
• Uncontrolled systemic and gastro-intestinal inflammatory conditions
• Bone marrow dysplasia
• History of auto-immune disease
• History of adverse reaction to vaccines
• Known history of positive tests for HIV/AIDS, hepatitis B or C
• Is pregnant or breastfeeding

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kael-GemVax Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Lytix Biopharma AS

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tone Nordøy, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Tromsø University Hospital

Locations

University Hospital North-Norway

Tromsø, , Norway

Countries

Norway

Other Identifiers

C09-315-02

Identifier Type: -

Identifier Source: org_study_id